Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Posts Mild Q2 Revenue Growth, Significant Cut in Net Loss

NEW YORK, Aug. 14 (GenomeWeb News) - Genaissance Pharmaceuticals posted a modest increase in second-quarter revenue amid decreased R&D spending and substantially narrowed net losses.


Total revenue for the period ended June 30 inched up to $3.1 million from $1.9 million one year ago.


R&D spending, meantime, dipped to $5 million from $6.6 million. As a result, net loss in the second quarter receded to $3.8 million, or $.17 per share, from $13.5 million, or $.59 per share, in the second quarter last year.


Genaissance said it had around $23.3 million in cash, cash equivalents, and marketable securities as of June 30.


Click here for more information.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.